| PRECLINICAL | evidence | Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial. | Semaglutide | — | 2026-07-02 |
| PRECLINICAL | evidence | Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice. | Semaglutide | — | 2026-07-02 |
| PRECLINICAL | evidence | Semaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression. | Semaglutide | — | 2026-07-02 |
| PRECLINICAL | evidence | Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. | Semaglutide | — | 2026-07-02 |
| PRECLINICAL | evidence | Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. | Semaglutide | Weight & fat loss | 2026-07-02 |
| PRECLINICAL | evidence | Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | The systems medicine view of semaglutide: from clinical trials to molecular mechanisms. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Semaglutide in Schizophrenia-A Top Clinical Trial. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8). | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy. | Ozempic | — | 2026-07-01 |
| PRECLINICAL | evidence | Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements. | Ozempic | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Modified case-crossover estimators were unbiased in the presence of temporal trends in the exposure of interest: a simulation study. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus. | Semaglutide | Liver health | 2026-07-01 |
| PRECLINICAL | evidence | The Ethics of Wegovy in Pediatric Mental Health. | Ozempic | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society. | Ozempic | — | 2026-07-01 |
| PRECLINICAL | evidence | Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | "Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation. | Ozempic | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study. | Wegovy | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study). | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review. | Semaglutide | Weight & fat loss | 2026-07-01 |
| PRECLINICAL | evidence | Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | GLP-1 RA semaglutide for alcohol use disorder: a potential multi-target therapy. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Deja vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional optimization. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Integrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney disease. | Semaglutide | Glycemic control | 2026-07-01 |
| PRECLINICAL | evidence | Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Structural Assumptions in Semaglutide Cost-Effectiveness. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Structural Assumptions in Semaglutide Cost-Effectiveness-Reply. | Semaglutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Severe Perioperative Lactic Acidosis and Hyperglycemia Responsive to Thiamine in a Patient With Prior Semaglutide Use and Restrictive Dieting: A Case Report. | Semaglutide | Glycemic control | 2026-07-01 |